As Missling stated, it has to do with drug pricing... which should be viewed as a favorable strategy for shareholders. I presume that AD NDA filing for TGA (and UK, EU) will be soon after FDA. There is no "compassionate use" in AU... other than an SAS for ongoing treatment for trial patients. It's possible that doctors could use SAS to gain access for their AD patients, but an application must be made.
Market Data 
Markets 
AI
